Predictive Factors and Management of Macular Edema after Retropupillary Iris-Claw Intraocular Lens Implantation in Aphakia: National Multicenter Audit-Report 2.

The aim of this multicenter, national clinical audit is to evaluate the predictive factors and management of postoperative macular edema (ME) after retropupillary iris-claw intraocular lens (RICI) implantation and pars plana vitrectomy (PPV). Preoperative, surgical and postoperative data were collected. Number and type of intravitreal injections (IT) administered (anti-VEGF or dexamethasone implant), visual acuity (VA), intraocular pressure (IOP) and central retinal thickness (CRT) assessed by OCT were collected at 1, 3, 6 and 12 months. From 325 eyes (325 patients), 11.7% (38/325) developed postoperative ME. Previous complicated cataract surgery with no capsular support was the only significant predictive factor for developing postoperative ME (OR 2.27, 95% CI 1.38-4.52, p = 0.02) after RICI implant. Mean time to ME development was 11.4 ± 10.7 weeks, and mean CRT peaked at 3 months follow-up. Different treatment options were non-steroidal anti-inflammatory (NSAIDs) drops (31.6%, 12/38), dexamethasone (DEX) implant (50%, 19/38), anti-VEGF (7.9%, 3/38) or combined IT (10.5%, 4/38). Cumulative probability of ME resolution was higher in the group treated with IT than in the group treated with topical NSAIDs (85.2% vs. 58.3%, p = 0.9). Performing RICI implantation after complicated cataract surgery is a risk factor for the development of postoperative ME. DEX implants may be an effective treatment for postoperative ME in these cases.

Solar maculopathy secondary to sunlight exposure reflected from the screen of mobile devices: two case reports.

BACKGROUND: Solar maculopathy is a well described clinical entity that usually occurs in patients that have gazed directly the sun. In this report we describe the first two cases of solar maculopathy in individuals exposed to sunlight reflected from the screen of mobile devices in the absence of direct sun gaze. CASES DESCRIPTION: Case 1. A 30-year-old Caucasic man presented with bilateral metamorphopsia, central scotoma and decreased visual acuity two days after being reading for four hours with his tablet computer in a terrace of a ski center. CASE 2: A 20-year-old Caucasic woman was examined for bilateral decrease of visual acuity and central scotoma after being at the beach the day before and reading with her mobile phone for 3 hours. Both patients denied gazing directly to sunlight at any moment. In each case, exploration revealed fundus and OCT images compatible with the typical features of solar maculopathy. After 2 years of follow-up, in absence of any specific treatment, Case 1 had a complete resolution of the fundus alterations, while Case 2 still presented defects of the outer retinal layers. In both cases, an exposure to sunlight reflected from the screen of their mobile devices was documented in environments where solar radiation is thought to be augmented. CONCLUSION: Sunlight reflection from a display screen needs to be considered as a possible risk factor for increased solar radiation and a subsequent risk of solar maculopathy.

RETROPUPILLARY IRIS-CLAW INTRAOCULAR LENS AND PARS PLANA VITRECTOMY IN APHAKIA MANAGEMENT: A National Multicenter Audit.

PURPOSE: To evaluate the outcomes and safety of retropupillary iris-claw intraocular lens implantation and associated pars plana vitrectomy. METHODS: Multicenter, national audit of 325 eyes (325 patients). Demographics, surgical details, and complications are described. Visual acuity, intraocular pressure, and central retinal thickness assessed by optical coherence tomography were collected at 1, 3, 6, and 12 months after surgery. Kaplan-Meier curves were created to assess the cumulative probability of postoperative visual acuity and intraocular pressure levels, macular edema development, and corneal decompensation. RESULTS: The cumulative probability of the final visual acuity ≤0.3 logarithm of the minimum angle of resolution (≥20/40 Snellen) was 75.6% at 12-month follow-up. The probability of intraocular pressure >21, ≥25, and ≥30 mmHg was 48.1%, 33.1%, and 19.0%, and the probability of intraocular pressure-lowering drops was 50.9% at 12 months. Glaucoma surgery was required in 4.3% of the eyes (14/325). The cumulative probability of macular edema was 20.5% at 12 months and was greater in complicated cataract surgery than in intraocular lens-luxation eyes (26% vs. 16.7%, P = 0.04). Corneal transplantation was required in 2.8% of the eyes (9/325). CONCLUSION: This study on 325 eyes with aphakia or intraocular lens dislocation managed with the retropupillary iris-claw intraocular lens technique provides clinical outcomes in a real-world scenario, reporting relevant data for patient counseling and preoperative discussions.

Sterile endophthalmitis after intravitreal injections.

Sterile endophthalmitis appears as an infrequent complication of intravitreal injections and seems to develop mainly in the context of the off-label use of drugs that have not been conceived for intravitreous administration. The aetiology of sterile endophthalmitis, independently of the administered drug, remains uncertain and a multifactorial origin cannot be discarded. Sterile inflammation secondary both to intravitreal triamcinolone acetonide and to intravitreal bevacizumab share many characteristics such as the acute and painless vision loss present in the big majority of the cases. Dense vitreous opacity is a common factor, while anterior segment inflammation appears to be mild to moderate. In eyes with sterile endophthalmitis, visual acuity improves progressively as the intraocular inflammation reduces without any specific treatment. If by any chance the ophthalmologist is not convinced by the sterile origin of the inflammation, this complication must be treated as an acute endophthalmitis because of the devastating visual prognosis of this intraocular infection in the absence of therapy.

Primary 23-gauge sutureless vitrectomy for rhegmatogenous retinal detachment.

AIMS: To report a prospective non-comparative consecutive interventional study on the safety and efficacy of 23-Gauge transconjunctival sutureless pars plana vitrectomy for primary rhegmatogenous retinal detachment (RRD). MATERIALS AND METHODS: Fifty eyes of 50 consecutive patients were recruited between June 2007 and January 2008. All surgeries were performed using the one-step 23-Gauge system with angled incisions. The surgical protocol consisted of a minimum of eight clinical visits: baseline, 1 day, 1 week, 1-, 3- and 6- months after the initial surgery. The endpoints were anatomical, functional results and complications arising from the surgery. RESULTS: Anatomical success was achieved in 82% of cases (41 out of 50) with single surgery and rose to 98% (49 out of 50) with additional surgery. Mean visual acuity improved from logMAR 0.48(SD 0.36) to 0.26(SD 0.31), P < 0.001. Two cases with ocular hypotony, defined as an intraocular pressure ≤ 6mmHg, that were associated with a choroidal detachment were seen. CONCLUSIONS: Acceptable anatomical and functional success rates can be achieved with primary 23-Gauge transconjunctival sutureless vitrectomy for RRD. We found that the approach technique is different from conventional vitrectomy and the complications arising from post surgical hypotony and leakage from sclerotomies are potentially higher compared to 20-Gauge vitrectomy.

Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect?

AIMS: To report the early development of epiretinal membranes (ERM) in eyes with retinal vein occlusions (RVO) treated with intravitreal bevacizumab and to describe possible mechanisms that may be involved in the growth and contraction of these lesions. METHODS: Retrospective and interventional study that included 25 eyes of 25 patients with RVO (16 eyes with central retinal vein occlusion and nine eyes with branch retinal vein occlusion). After an initial 2.5mg/0.1ml intravitreal bevacizumab injection all patients were followed-up every 6 weeks. Re-treatments were based on visual acuity and optical coherence tomography findings. Results Twenty-five eyes were treated with bevacizumab and followed for 8.3 (range 4.5-13.5) months. Four eyes developed an ERM within 6-7weeks after the administration of bevacizumab. ERM was not associated with further deterioration of visual acuity or metamorphopsia in these patients. A rebound of macular oedema was observed in one patient with ERM and in two other patients. No other side effects were observed. CONCLUSIONS: Intravitreal bevacizumab may be associated with an early growth of ERM in eyes with RVO, although a causative relationship cannot be established. Future randomised clinical trials are necessary to determine the efficacy and safety profile of this novel therapy.

Early unilateral macular sensitivity changes in microperimetry in a case of pituitary adenoma.

The value of the MP-1 microperimeter in early diagnosis of pituitary tumours by detection of changes in macular sensitivity is described. A 21-year-old female presented with blurred vision in the right eye. Ophthalmic examination was unremarkable. Static perimetry of the central visual field (30°) was performed by use of a Humphrey automatic perimeter, and the retinal sensitivity of the 12 central degrees was measured by use of the MP-1. Static perimetry revealed a peripheral visual field defect without involvement of the macular region. The MP-1 revealed an important loss of sensitivity (3.4 ± 4.8 dB) in the central 12°. Magnetic resonance imaging revealed a pituitary adenoma with sellar and suprasellar extension. Three months after surgical removal, use of the MP-1 revealed complete recovery of the sensitivity (19.28 ± 2.5 dB), fixation location, and fixation stability of the right eye. In pituitary tumours, the presence of a sub-clinical form of macular involvement can be demonstrated and followed-up accurately by use of the MP-1.

Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?

PURPOSE: To evaluate the recurrence of vitreous hemorrhage (VH) in patients treated with intravitreal bevacizumab (IVB) injection (2.5 mg/0.1 mL) intraoperatively at the end of vitrectomy for treatment of diabetic nonclearing VH. METHODS: A prospective pilot study of 30 eyes of 28 consecutive diabetic patients who underwent pars plana vitrectomy and IVB injection intraoperatively at the end of vitrectomy was performed. The amount of VH was graded with slit lamp biomicroscopy by three masked retinal specialists from grade 0 to grade 3. Main outcome measures were rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. RESULTS: The percentage of severe recurrent VH with no fundus details (grade 3) was 7%, 13%, 27%, and 30%, respectively, at 7 days and 1-, 3-, and 6-month follow-up. At 6-month followup, the best-corrected visual acuity improved from 1.00 to 0.4 logMAR (p=0.01) in 21 out of 30 eyes (70%). Nine out 20 (40%) phakic patients developed cataract during the follow-up period, and 7 (31%) of them underwent cataract surgery. CONCLUSIONS: The study suggests that intravitreal bevacizumab injection cannot prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous hemorrhage.

Enzymatic vitreolysis.

In the absence of posterior vitreous detachment, vitreous cortex is adhered to the internal limiting lamina of the inner retina. This junction between the vitreous and the retina is thought to participate in the pathophysiology of diverse retinal diseases, including proliferative diabetic retinopathy and diabetic macular edema. Vitrectomy has been associated with decrease of macular edema and improvement of visual acuity in eyes of diabetic patients. Thus, many pharmacologic agents have been studied with the aim of inducing a posterior vitreous detachment in order to facilitate the surgical procedure and reduce complications of vitrectomy. More recently, different agents such as plasmin and microplasmin have shown to be able to induce a posterior vitreous detachment given as a single intravitreal injection. The aim of this article is to give a scope about the pharmacologic vitreolysis and posterior vitreous detachment studies and describe some ongoing clinical trials that will determine the efficacy and safety of these novel therapies for diabetic retinopathy.

Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization.

PURPOSE: To evaluate visual acuity changes and safety of combined treatment with photodynamic therapy (PDT) and intravitreal triamcinolone acetonide (IVTA) in myopic eyes with choroidal neovascularization (CNV). DESIGN: Prospective interventional case series. METHODS: Twelve eyes of 12 patients with subfoveal myopic CNV were treated with PDT followed by IVTA within a week. Changes in visual acuity and possible complications related to the combined therapy were assessed in periodic visits. RESULTS: After combined therapy, a significant increase in mean visual acuity was observed at one, three, and six months. A significant increase of mean intraocular pressure was observed after seven days, one month, and three months. Ten patients (83%) required topical antiglaucomatous therapy during follow-up. CONCLUSIONS: The combination of PDT and IVTA may increase the possibility of improving or stabilizing visual acuity in patients with subfoveal myopic CNV, but further studies are needed to asses the effects of this treatment.

Pterygium surgery: conjunctival autograft using a fibrin adhesive.

PURPOSE: To evaluate the efficiency and safety of using a fibrin adhesive (Tissucol Duo, Baxter AG, Vienna, Austria) to avoid the need for sutures during conjunctival autograft surgery for primary pterygium. METHODS: Twenty patients (20 eyes) with primary nasal pterygium were subjected to conjunctival autograft surgery. The free conjunctival graft placed over the bare sclera was fixed to the surrounding conjunctiva and cornea using the fibrin glue. An occlusive patch was applied. The outcome of surgery and any possible complications were periodically assessed. RESULTS: Mean patient age was 54.9 years (28-75 years). The mean follow-up time was 26.05 +/- 3.15 (SD) weeks. The time of surgery was 15 to 20 minutes. During the postoperative course, none of the patients felt pain, and only 5/20 (25%) had the mild sensation of the presence of a foreign body. In 18/20 (90%) patients, the conjunctival autograft was observed to be correctly positioned and fixed in all the follow-up exams. No sutures were used during or after surgery. There were no cases of regrowth of the pterygium. CONCLUSION: Our findings demonstrate the safety and efficiency of Tissucol Duo as a conjunctival adhesive for pterygium autograft surgery as treatment of primary pterygium. Because of its fast and easy application, this product considerably reduces the time of surgery. Its use also avoids complications derived from sutures and diminishes the sensation of a foreign body in the eye following surgery.

Intravitreal triamcinolone for the treatment of diabetic macular edema.

Diabetic macular edema is one of the leading causes of visual loss in first world countries and the first cause in diabetic retinopathy. The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular edema, more specifically defined as clinically significant macular edema. Nevertheless, progressive visual loss is found in the 26% of patients with diabetic macular edema treated with photocoagulation. The failure of laser treatment and the destructive nature of the therapy has forced researchers to pursue new alternatives including vitrectomy with or without internal limiting membrane peels, the use of proteinkinase C inhibitors, intravitreal injections of antibodies that inhibit the vascular endothelial growth factor, somatostatin analog, or the intravitreal injection with corticosteroids. Triamcinolone acetonide is glucocoticosteroid with antiangiogenic and antiedematous properties. Publications evaluating the safety and efficacy of intravitreal injection of triamcinolone in the treatment of diabetic macular edema show varying outcomes with respect to the increases of visual acuity and decreases in foveal thickness. Despite this, intravitreal triamcinolone is a treatment that has evolved quickly and is considered increasingly useful.

Evaluación de la efectividad de las normas terapéuticas propuestas en el Hospital Clínico Universidad de Chile, para neumonía e infección urinaria / Evaluation of efectivity of therapeutic standards proposed at Universidad de Chile clinical hospital, for pneumonia and urinary infections

Introducción: dado el creciente interés que existe en desarrollar y aplicar guías clínicas en las instituciones de salud, con el objeto de asegurar una calidad homogénea de atención y ayudar a manejar los costos de la atención médica, se decidió evaluar la efectividad de los esquemas terapéuticos sugeridos en las normas terapéuticas elaboradas recientemente en el Hospital Clínico de la Universidad de Chile con el objeto de determinar que los esquemas sugeridos son, al menos, tan efectivos como otros esquemas usados en nuestra institución. Objetivo: evaluar la efectividad de los esquemas terapéuticos sugeridos en las normas terapéuticas del Hospital Clínico de la Universidad de Chile para neumonía e infección urinaria, en términos de: días de hospitalización, días de fiebre, complicaciones y letalidad. Metodología: se usó un diseño observacional prospectivo, en que la decisión de usar los esquemas sugeridos en las normas fue de los médicos tratantes en el momento del ingreso de los pacientes, con lo que se conformaron dos grupos, los que fueron seguidos por los investigadores desde el momento del ingreso al hospital hasta su alta, consignándose los parámetros más arriba referidos para la evaluación de la efectividad más edad, sexo y diagnóstico. Ambos grupos fueron posteriormente comparados, para establecer si existián diferencias en relación a los parámetros usados. Resultados: no se encontraron diferencias estadísticamente significativas en realación a edad, sexo ni tipo de diagnóstco en los grupos estudiados. En relación a los parámetros usados para medir efectividad los resultados en el grupo que cumplió con las normas terapéuticas fueron (promedio ñ desviación estánder): días de hospitalización: 111 ñ 6,2 días, días de fiebre: 5,2 ñ 5,1 días, complicaciones: 2,04 por ciento, letalidad: 0 por ciento; y en el grupo que no cumplió con las normas terapéuticas: días de hospitalización: 12,2 ñ 8,6 días con fiebre: 3,8 ñ 6,4, complicaciones 10,2 por ciento, letalidad: 2,04 por ciento. Estas diferencias no fueron estadísticamente significativas. Si los mismos parámetros se analizan de acuerdo a categorías diagnósticas (neumonía e infección urinaria), tampoco se encontraron diferencias estadísticamente significativas, aunque en los pacientes con infección urinaria que no cumplieron con las normas, se encontró un número menor de días con fiebre y esta diferencia estuvo en los límites de la significación estadística

Neumonía durante el embarazo: experiencia de un hospital universitario y revisión del tema / Pneumonia during pregnancy: an university hospital experience and review of the issue

La neumonía que se presenta durante el embarazo (NE) es una complicación infecciosa poco frecuente. En 10 años, catorce pacientes embarazadas fueron internadas por neumonía en un hospital universitario. Durante ese período se registraron 44.184 partos. La presentación clínica de nuestra serie fue clásica. Un 86 por ciento de las pacientes presentó un síndrome de condensación. La radiografía de tórax mostró en todas un infiltrado concordante con el diagnóstico de neumonía. Las principales complicaciones observadas fueron la insuficiencia respiratoria aguda parcial (57 por ciento), de evolución favorable en todas las pacientes y la asociación con parto prematuro (29 por ciento). Se logró obtener muestras respiratorias valorables en 5 pacientes, aislándose en dos de ellos streptococcus pneumoniae en secreción bronquial. Todas las NE se trataron inicialmente con betalactámicos, destacando penicilina sódica en 9 (64 por ciento) y cefalosporinas en 5 (36 por ciento) pacientes. La resolución clínica de la neumonía fue completa al alta. Nuestros datos sugieren que la NE es una complicación poco frecuente y de bajo riesgo materno-fetal